Acción CALTX CALLIDITAS THERAPEUTICS AB
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Calliditas Therapeutics AB

Acciones

CALTX

SE0010441584

Diferido Nasdaq Stockholm
Otros sitios de cotización
 12:59:42 30/04/2024 		Varia. Cinco días. Varia. 1 de enero.
110 SEK +2,90 % Gráfico intradía de Calliditas Therapeutics AB +9,56 % -13,45 %
25/04 La renta variable europea cotizó en EE.UU. como recibos de depósito estadounidenses con una modesta tendencia al alza en la sesión del jueves MT
24/04 Calliditas Therapeutics afirma que el estudio OLE muestra una respuesta al tratamiento coherente con los hallazgos del estudio NefIgArd de fase tardía MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading
Calliditas Therapeutics' 2023 Annual Report Published
Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings
Calliditas Announces Positive NefIgArd Open Label Extension Results
Calliditas Therapeutics AB Announces Positive NefIgArd Open Label Extension Results
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Calliditas Therapeutics AB Presents Additional Data Analyses from the Phase 3 NeflgArd Trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
Calliditas Therapeutics to Attend Conferences in April
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
Calliditas Therapeutics AB to Present Nefecon Data At the ISN World Congress of Nephrology in Buenos Aires
Calliditas Therapeutics Gets US Patent Allowance for Cancer Treatment Inhibitor
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción CALTX
  4. Noticias Calliditas Therapeutics AB
  5. Otros idiomas